THANK YOU FOR SUBSCRIBING
This acquisition advances Sanofi’s ongoing R&D transformation to fuel the development of the most promising medicines that will address significant patient needs.
FREMONT, CA: Sanofi is about to acquire all of the outstanding shares of Principia Biopharma, a South San Francisco, CA-based late-stage biopharmaceutical company focused on developing treatments for immune-mediated diseases, for $100 per share in cash, which represents an aggregate equity value of nearly $3.68 billion (on a fully diluted basis).
The Sanofi and Principia Boards of Directors unitedly approved the transaction.
Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.
This acquisition advances Sanofi’s ongoing R&D transformation to fuel the development of the most promising medicines that will address significant patient needs.
Principia’s Bruton tyrosine kinase (BTK) inhibitors add to Sanofi’s efforts to boost and build a portfolio of the next generation of transformative treatments for autoimmune diseases. BTK is present in the signaling pathways of key innate and adaptive cell types of the immune system. Disrupting or blocking these signaling processes can help stop inflammation and tissue destruction in relation to autoimmune diseases and target some of the underlying pathophysiology.
The Principia BTK inhibitor franchise is based on its proprietary Tailored Covalency platform that allows the design of both reversible covalent and irreversible covalent small molecule inhibitors that are more selective with less off-target effects. The optimized target residence time has immense potential to deliver the desired efficiency with a stronger safety profile.
In 2017, Sanofi formed a partnership with Principia under which Principia granted Sanofi an exclusive, worldwide license to develop and commercialize BTK inhibitor ‘168 in multiple sclerosis and other central nervous system diseases.
“This acquisition advances our ongoing R&D transformation to accelerate development of the most promising medicines that will address significant patient needs,” said Paul Hudson, Sanofi Chief Executive Officer. “The addition of multiple BTK inhibitors to our pipeline demonstrates our commitment to strategic product acquisitions in our priority therapeutic areas. Full ownership of our brain-penetrant BTK inhibitor ‘168 removes complexities for this priority development program and simplifies future commercialization.”
More in News